The disclosure relates to methods for treating subjects with musculoskeletal diseases or with muscle wasting not associated with a musculoskeletal disease by gene transfer with recombinant adeno-associated viruses (rAAV) encoding myostatin inhibitors such as follistatin-344. The rAAV are administered prior to development of diffuse muscle fibrosis in a subject, or the rAAV administration avoids regions of muscle fibrosis in a subject.
申请公布号
WO2016057975(A2)
申请公布日期
2016.04.14
申请号
WO2015US55022
申请日期
2015.10.09
申请人
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL